10-Q: Spero Therapeutics Q3 2025: Tebipenem HBr Advances, Programs Streamlined

Spero Therapeutics reports Q3 2025 results, highlighting the successful Phase 3 PIVOT-PO trial for tebipenem HBr and strategic program terminations to focus resources.

Summary

• Net loss for the three months ended September 30, 2025, was $7.4 million, a significant reduction from $17.1 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $22.9 million, down from $47.7 million for the nine months ended September 30, 2024.
• Total revenues for Q3 2025 were $5.4 million, compared to $13.5 million in Q3 2024, primarily due to decreased grant and collaboration revenue.
• Total revenues for the nine months ended September 30, 2025, were $25.5 million, compared to $32.9 million for the same period in 2024.
• Cash and cash equivalents stood at $48.6 million as of September 30, 2025.
• The accumulated deficit reached $482.6 million as of September 30, 2025.
• The pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy in May 2025; GSK plans to submit data for FDA filing in Q4 2025.
• Development of SPR206 was ceased in March 2025, and SPR720 development was ceased in November 2025, narrowing the company's pipeline.
• The company received the final $23.8 million development milestone payment from GSK in the third quarter of 2025.
• An impairment charge of $0.6 million was recorded in Q3 2025 related to a real estate lease right-of-use asset due to sublease agreements.
• The company received a Wells Notice from the SEC on January 9, 2025, regarding a preliminary determination to recommend civil enforcement action related to past public disclosures concerning tebipenem HBr.

Sentiment

Score: 7

Explanation: The company achieved a significant clinical milestone with tebipenem HBr, leading to an extended cash runway and reduced losses. However, the pipeline has narrowed due to program terminations, and the company faces an SEC Wells Notice, which introduces regulatory uncertainty and potential financial penalties. The overall sentiment is cautiously positive due to the clinical success and improved financial outlook, but tempered by the legal and pipeline risks.

Positives

• The pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy, indicating strong clinical results.
• GSK plans to submit the tebipenem HBr data for FDA filing during the fourth quarter of 2025, moving the product closer to potential commercialization.
• The company received the final $23.8 million development milestone payment from GSK in Q3 2025, strengthening its financial position.
• Net loss significantly decreased for both the three months ($7.4 million vs $17.1 million) and nine months ($22.9 million vs $47.7 million) ended September 30, 2025, compared to the prior year periods.
• Cash runway is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028, providing extended financial stability.
• Securities class action lawsuits and stockholder derivative actions against the company and certain former officers were dismissed or voluntarily dismissed.

Negatives

• The company ceased development of SPR206 in March 2025 and SPR720 in November 2025, significantly narrowing its product pipeline and increasing dependence on tebipenem HBr.
• Total revenues decreased for both the three months ($5.4 million vs $13.5 million) and nine months ($25.5 million vs $32.9 million) ended September 30, 2025, compared to the prior year periods.
• The company continues to incur significant operating losses and has an accumulated deficit of $482.6 million as of September 30, 2025.
• A Wells Notice was received from the SEC on January 9, 2025, contemplating a civil enforcement action, which could result in significant penalties and reputational harm.
• An impairment charge of $0.6 million was recorded in Q3 2025 related to a right-of-use asset, reflecting a reduction in asset value.

Risks

• Business and prospects are substantially dependent on the tebipenem HBr program and collaboration with GSK; failure to execute or termination of the GSK agreement could materially adversely affect the business.
• Ability to realize the value of tebipenem HBr depends on obtaining FDA approval, and the timeline or requirements of such approval may impact commercialization attractiveness.
• Clinical trials may fail to produce favorable results, leading to additional costs or delays in completing development.
• Serious adverse events or undesirable side effects of product candidates may be identified during development or after approval, potentially delaying or preventing regulatory approval or limiting commercial potential.
• Even if a product candidate obtains regulatory approval, it may not achieve market acceptance by physicians, patients, hospitals, and third-party payors.
• Inability to establish sales, marketing, and distribution capabilities or enter into sales, marketing, and distribution agreements with third parties.
• Substantial competition from other pharmaceutical and biotechnology companies could adversely affect operating results.
• History of losses and expectation of substantial future losses; inability to obtain additional capital could limit operations.
• Failure to achieve milestones triggering payments in existing or future license and collaboration agreements.
• Reliance on third parties for the manufacture of clinical supplies increases the risk of insufficient quantities or unacceptable costs.
• Failure to comply with obligations in in-license or acquisition agreements could lead to the loss of important rights.
• Use of government funding for programs adds complexity and may impose requirements that increase commercialization and production costs.
• Inability to obtain and maintain sufficient patent protection or if the scope of protection is not sufficiently broad.
• Failure to enforce registered trademarks or secure registration of pending trademark applications.
• Delays in obtaining required regulatory approvals will materially impair the ability to commercialize product candidates and generate revenue.
• The price of common stock has been and may continue to be volatile, potentially resulting in a decline in value for stockholders.
• The Wells Notice from the SEC contemplating a civil enforcement action could have a material adverse effect on business, financial condition, results of operations, prospects, and/or stock price.
• Past failure to maintain Nasdaq Global Select Market listing requirements and potential future failure could negatively affect stock price and liquidity.
• Product liability lawsuits could divert resources, cause substantial liabilities, and limit commercialization.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Internal computer systems or those of contractors may fail or suffer cybersecurity incidents, disrupting product development programs.
• Actual or perceived failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation, and/or adverse publicity.
• Adverse effects from natural disasters and/or health epidemics on business, financial condition, and results of operations.
• Ability to use net operating loss carryforwards may be limited due to ownership changes or tax law provisions.
• Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, and government shutdowns could hinder timely approval.
• Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China, may adversely impact business and operating results.
• Future success depends on the ability to retain key executives and to attract, retain, and motivate qualified personnel.
• Internal restructuring activities could result in business disruptions or materially harm results of operations.
• Additional risks in conducting business in international markets if foreign approvals are obtained.
• Broad discretion in the use of cash reserves may not be effective.
• Reduced disclosure requirements as a smaller reporting company may make common stock less attractive to investors.
• Increased costs as a public company and management time devoted to compliance initiatives.
• Failure to maintain effective internal controls in accordance with Section 404 of Sarbanes-Oxley.
• Sales of a significant portion of total outstanding shares could cause the market price of common stock to decline.
• No anticipated cash dividends; stockholders must rely on capital appreciation.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts to replace management.
• Involvement in securities litigation could divert management's attention and harm the business.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future, at least for the next year. Based on current cash and cash equivalents and reduced clinical expenses from program completions, the cash runway is projected to fund operations into 2028. Beyond this period, or if the operating plan changes, additional funding will be required, which the company plans to seek through equity offerings, debt financings, government funding, collaborations, strategic alliances, or licensing arrangements. The primary focus will be on finalizing Phase 3 clinical trial activities for tebipenem HBr under the GSK License Agreement.

Management Comments

• We believe this re-prioritized strategic focus is the best way to optimize our financial and other resources to advance our goal of identifying and developing novel treatments for rare diseases and diseases caused by MDR bacterial infections with high unmet need.
• We expect to continue to incur significant expenses and operating losses for at least the next year.
• Based on our cash and cash equivalents as of September 30, 2025 and the decrease in clinical expense as a result of the completion of the PIVOT-PO Phase 3 trial for tebipenem HBr and the decision to cease development of SPR720, we believe that our cash runway will be sufficient to fund our operating expenses and required capital expenditures into 2028.

Industry Context

Spero Therapeutics operates in the highly competitive clinical-stage biopharmaceutical industry, specializing in novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, an area with significant unmet medical needs. The successful Phase 3 trial for tebipenem HBr positions it as a potential first broad-spectrum oral carbapenem for complicated urinary tract infections (cUTIs), addressing the growing challenge of antibiotic resistance where existing therapies are becoming less effective. The industry is characterized by high R&D costs, lengthy regulatory processes, and a reliance on strategic partnerships and government funding, as evidenced by Spero's collaboration with GSK and government awards. Broader macroeconomic factors, including inflation, interest rate volatility, and evolving trade policies, also influence the operational and financial landscape for companies in this sector.

Comparison to Industry Standards

• Tebipenem HBr, if approved, would compete with established oral therapies for cUTIs such as Levaquin, Cipro, and Bactrim, which are widely accepted but face waning susceptibility.
• The product would also compete with IV-administered treatments for Gram-negative infections, including Avycaz (ceftazidime-avibactam) from Allergan plc and Pfizer, Zerbaxa (ceftolozane-tazobactam) from Merck & Co., and Vabomere (meropenem-vaborbactam) from CorMedix Inc.
• The potential pricing of tebipenem HBr at a significant premium over existing competitive products could pose a challenge for market penetration and acceptance.

Management Changes

Corporate Governance

Legal Proceedings

• Two putative class action lawsuits (Richard S. Germond v. Spero Therapeutics, Inc. and Kashif Memon v. Spero Therapeutics, Inc.) were consolidated and subsequently dismissed by court order on September 30, 2024, with the case closed on October 28, 2024.
• Two stockholder derivative actions (Marti v. Mahadevia, et al. and Heil v. Mahadevia, et al.) were voluntarily dismissed by the plaintiffs on March 31, 2025, and March 20, 2025, respectively.
• The company received a Wells Notice from the SEC on January 9, 2025, indicating a preliminary determination to recommend a civil enforcement action or administrative proceeding against the company, its former CEO (Ankit Mahadevia, M.D.), and its former CFO/President/CEO (Satyavrat Sath Shukla). The action relates to public disclosures from March 31, 2022, to May 3, 2022, concerning the tebipenem HBr NDA and potential violations of federal securities laws. The company maintains its disclosures were appropriate and is cooperating with the SEC.

Related Party Transactions

• Collaboration revenue related party from the GSK License Agreement totaled $3.0 million for the three months ended September 30, 2025, and $19.9 million for the nine months ended September 30, 2025.
• The company received the final $23.8 million development milestone payment from GSK in the third quarter of 2025.
• The collaboration receivable related party decreased by $48.5 million due to the receipt of the third and fourth installment payments from GSK.
• A deferred revenue related party balance of approximately $2.4 million from the GSK License Agreement remains on the balance sheet.

Stakeholder Impact

• Shareholders: Potential for increased value from tebipenem HBr's clinical success and progress towards FDA filing, but also face risks from pipeline narrowing, potential dilution from future capital raises, and uncertainty surrounding the SEC Wells Notice. Stock price volatility is a noted risk.
• Employees: Experienced a workforce reduction in October 2024 due to restructuring, but retention awards were approved for both non-executive and executive employees to maintain key personnel.
• Customers/Patients: The advancement of tebipenem HBr offers the potential for a new oral treatment option for complicated urinary tract infections, addressing a high unmet medical need for drug-resistant infections.
• Partners (GSK): The collaboration with GSK continues to be central to the development and potential commercialization of tebipenem HBr, with GSK responsible for further development and commercialization costs in its territory.
• Regulatory Bodies (FDA, SEC): Ongoing engagement with the FDA for tebipenem HBr approval, and an active SEC investigation and Wells Notice pose significant regulatory and legal challenges for the company.

Next Steps

• GSK plans to submit the data from the PIVOT-PO trial as part of an FDA filing during the fourth quarter of 2025.
• The company plans to prioritize finalizing the Phase 3 clinical trial activities for tebipenem HBr under the GSK License Agreement.
• The company anticipates receipt of the remaining $0.4 million milestone payment from GSK (related to Amendment 4) in the fourth quarter of 2025.
• The company expects to require additional funding beyond its current cash runway (into 2028) and may seek additional capital through various financing mechanisms.

Key Dates

Recommendation

While the successful Phase 3 trial for tebipenem HBr and the extended cash runway are significant positive developments, the company's pipeline has narrowed considerably with the termination of SPR206 and SPR720. The ongoing SEC Wells Notice introduces substantial regulatory and legal uncertainty, which could lead to significant penalties or reputational damage. The stock has potential upside if tebipenem HBr gains FDA approval and commercial success, but the risks associated with a concentrated pipeline and the SEC investigation warrant a cautious 'hold' stance for investors until these uncertainties are resolved.

Keywords

Spero Therapeutics, SPRO, biopharmaceutical, clinical-stage, tebipenem HBr, cUTI, complicated urinary tract infections, pyelonephritis, FDA approval, GSK, GlaxoSmithKline, Phase 3 trial, PIVOT-PO, antibiotic resistance, drug development, SEC Wells Notice, financial results, Q3 2025, pharmaceutical, biotechnology, SPR206, SPR720, pipeline, restructuring